Compare FICO & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | ZTS |
|---|---|---|
| Founded | 1956 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 31.2B |
| IPO Year | 1995 | 2012 |
| Metric | FICO | ZTS |
|---|---|---|
| Price | $1,188.48 | $81.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $1,689.92 | $154.18 |
| AVG Volume (30 Days) | 312.4K | ★ 6.8M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | ★ 29.78 | 10.05 |
| EPS | ★ 17.73 | 1.42 |
| Revenue | $1,032,475,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $27.28 | $5.63 |
| Revenue Next Year | $16.97 | $4.77 |
| P/E Ratio | $68.82 | ★ $57.25 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $870.01 | $73.82 |
| 52 Week High | $1,998.01 | $167.38 |
| Indicator | FICO | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 41.22 |
| Support Level | $1,068.67 | $74.35 |
| Resistance Level | $1,323.35 | $82.34 |
| Average True Range (ATR) | 63.40 | 2.21 |
| MACD | -8.58 | 1.81 |
| Stochastic Oscillator | 29.99 | 83.23 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.